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In this commentary, the authors put forward a case for greater use of continuous glucose 
monitoring (CGM) in older people with diabetes to aid deprescribing and avoidance of 
hypoglycaemia rather than using HbA1c targets. 
 
Diabetes mellitus is a complex chronic illness often accompanied by multiple co-morbidities 
and polypharmacy in the older person .  Worldwide, there are about 425 million people living 
with diabetes, of whom approximately 123 million are aged between 65 to 99 years.   
 
The aim of diabetes management is to achieve optimum glycaemic control, in order to 
prevent long-term microvascular, macrovascular and neurological complications.  Glycated 
haemoglobin (HbA1C) is currently the key surrogate marker for long-term diabetes control 
and complications. However, HbA1C is depicts only a single estimate of average glucose 
over the last 2–3 months, and fails to give information on glucose fluctuations or variability 
in the patient’s daily life.  An established method of capturing glucose levels on a day to day 
basis is via finger-prick testing (self-monitoring of blood glucose (SMBG)).  However, a 
Cochrane review reported that SMBG did not provide consistent long-term improvements in 
glycaemic control for non-insulin users with Type 2 diabetes(1). 
 
The challenge regarding the evidence-based management of diabetes in older people is that 
the bulk of the underlying data comes from randomized controlled trials in younger 
participants.  Lipska et al have pointed out that older people may not benefit from tight 
glycaemic control in the same way that younger adults do, and that older people are prone to 
serious adverse effects of hypoglycaemia from intensive therapy targeted at lowering HbA1C 
(2).  Various guidelines for the management of diabetes in older people have been developed, 
which contain recurring themes such as adopting a more personalised approach taking into 
account each person’s co-morbidities, frailty, polypharmacy and life expectancy (3). 
 
Despite these guidelines, recent studies have found that older people with type 2 diabetes are 
still at risk of being overtreated with diabetes drugs.  Hambling et al found that nearly a third 
of older people with type 2 diabetes living in Norfolk, England, were on potentially 
hazardous agents such as sulfonylureas and/or insulin, despite presence of comorbidities such 
as chronic kidney disease or dementia that substantially increase the risk of serious adverse 
effects (4).   
   
 
   
 
 
There are well-recognized hazards from use of sulfonylureas and insulin in older people, who 
are at particular risk of hypoglycaemia. Symptoms of hypoglycaemia are person-specific and 
can change with advancing age, due to changes in the hormonal response to 
hypoglycaemia(5). This is a particular problem in those with cognitive decline who may not 
be able to recognize symptoms of hypoglycaemia, or to take action in monitoring blood 
glucose and self-treating the hypoglycaemia.  Feinkohl et al in the Edinburgh Type 2 
Diabetes Study found that those with cognitive impairment had a twofold higher incidence of 
severe hypoglycaemia over 4 years. In addition, severe hypoglycaemia was associated with a 
steeper decline in cognitive function(6). 
 
Insulin has been shown to be the second most common medication associated with accident 
and emergency visits or hospitalisation(7).  We have identified major consequences such as 
falls and fractures, mortality and cardiovascular events in older people who have suffered 
severe hypoglycaemia (8). 
 
Here, the major challenge is difficulty in detecting and recording hypoglycaemia.  The 
disadvantage of widely-used finger prick SMBG is that it will only provide a snapshot of an 
individual’s glucose levels as and when that person makes a conscious decision to test.  This 
is problematic in an older person who may not recognise symptoms of hypoglycaemia and/or 
has cognitive problems.  In addition, neither finger-prick or HbA1c testing provide any 
insight into trends and variability throughout an entire 24 hour period, as there are no 
continuous measurements.  In order to illustrate the weakness of HbA1C as a marker, we 
have come up with simulated examples in Figure 1 (based on models presented by Vigersky 
et al.), where three people with completely contrasting daily glucose variation could turn out 
to have similar measured HbA1c (9). 
 
Figure 1 Simulated examples of blood glucose variability throughout the day in three 
patients who may have similar HbA1C readings (9) 
 
 
Whilst HbA1c is currently still recognised as the key surrogate marker to gauge average 
treatment efficacy, we argue that the inability to measure hypoglycaemia or capture day to 
   
 
   
 
day variability, renders it completely uninformative when addressing hypoglycaemia risk and 
optimizing benefit-harm balance of drug therapy in older people with diabetes.  
 
More importantly, the advent of continuous glucose monitoring (CGM) is a major step 
forward in enabling round the clock capture of hypoglycaemic episodes (especially at night 
where the patient may be asleep) and assessment of variability in glucose readings throughout 
the 10-14 day lifespan of a sensor.  Current day CGM systems comprise of a sensor sitting 
just under a patient’s skin that measures interstitial glucose levels Results can either be 
accessed by the patient through swiping a reader over the sensor or can be transmitted 
remotely via Bluetooth.  Alarms can be set to indicate if glucose levels go too high or low.  
Newer CGM devices allow real-time sharing of data with either a carer (in older people with 
cognitive difficulties) or parents (in children with type 1 diabetes).  
 
A systematic review of studies using CGM in older people found that hypoglycaemic 
episodes were occurring in 28-65% of participants with most of those episodes (80%) being 
asymptomatic (and thus likely to have gone undetected if the patients were not fitted with the 
CGM device) (10).  Despite the technological challenges and concerns about user-
friendliness, recent studies using CGM in older people have shown that older people and their 
carers find the devices acceptable and helpful in the management of their diabetes (11). 
 
The wealth of data captured by CGM has led to a rethink of how the findings should be 
interpreted to guide prescribing of diabetes medications. CGM measurements provide 
information on the percentage of readings and time spent per day within target, below target 
or above target.  An international panel of experts has produced recommendations for clinical 
targets for CGM data(12).  Importantly, for older adults the recommendation is to have less 
than 15 minutes per day exposed to hypoglycaemia (below 3.9 mmol/L), whilst having more 
than twelve hours per day between in the optimal range of 3.9-10 mmol/L. 
 
Instead of focusing on HbA1C, clinicians should, with the aid of CGM, interpret “time in 
range” to inform and tailor an individual’s diabetes medication.  Indeed, CGM can be 
considered as a particularly sophisticated form of therapeutic drug monitoring where the 
body’s response to the drug can constantly be evaluated to guide accurate medication 
regimens. In older people with diabetes who are at high risk of adverse effects, CGM enables 
fine and regular adjustments to the drug regimen to achieve an acceptable balance between 
   
 
   
 
benefit and harm, without the pain and inconvenience of frequent finger-prick testing. 
Clinicians and patients may be more confident and motivated to proceed with de-prescribing 
of sulfonylureas and insulin if CGM reveals hypoglycaemic episodes that they were 
completely unaware of. 
 
There are a number of important issues with regards to further research and implementation 
of CGM: 
• How often should CGM be used in older people with diabetes who are at high risk of 
hypoglycaemia, and is intermittent use a valid approach? 
• Can interpretation of the CGM findings and changes to medication (such as de-
prescribing of insulin and sulfonylureas) be safely conducted in primary care? 
• Can deployment CGM ultimately lead to reduction in serious hypoglycaemia episodes 
and hospital admission in older people with diabetes? 
 
At present, the availability of CGM for older people with diabetes has not been a priority in 
publicly-funded health services.  For instance, in England, the National Health Service has 
prioritized CGM for patients with type 1 diabetes.  There is no explicit mention of the role of 
CGM in older people with type 2 diabetes on medications which carry a high risk of 
hypoglycaemia (insulin, sulfonylureas), and who may need carer support (for example due to 
underlying dementia) with the management of their diabetes.  The availability and costs of 
CGM for medical practice in developing and/or middle income countries is a challenge.  If 
CGM were to be used intermittently in older people with diabetes, research will need to be 
carried out to prove that its costs can be offset by rationalising diabetes medications and 
reduction in adverse events (eg emergency attendances, hospitalisations, falls and fractures). 
 
The healthcare community has to seriously think about older people with diabetes (especially 
those on insulin or sulfonylureas, as well as memory problems) and how best to manage 
diabetes in later life.   
 
The focus should be on minimisation of hypoglycaemia through careful CGM-guided 
adjustment of drug therapy, rather than the relentless pursuit of HbA1c targets.  This will 
require an enormous shift in mindset by healthcare professionals and policy makers. Is it 
   
 
   
 
really appropriate in a 90-year old patient with diabetes to pursue an HbA1c target whose 
main benefit is reduction of long-term complications in the next 10 or 20 years?   
We have to realise that avoiding immediate harm from hypoglycaemia in older people with 
diabetes is far more pertinent than using HbA1c targets.  It is time to rethink. 
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